ライフサイエンスコーパス: liposomal amphotericin B

1 (556 receiving caspofungin and 539 receiving liposomal amphotericin B).

2 %); 35 patients (53%) were also treated with liposomal amphotericin B.

3 burden, with an efficacy similar to that of liposomal amphotericin B.

4 uced tissue fungal burden when combined with liposomal amphotericin B.

5 ring treatment with meglumine antimoniate or liposomal amphotericin B.

6 mmon (37.0%), mainly with an echinocandin or liposomal amphotericin B.

7 atio to receive either a single high dose of liposomal amphotericin B (10 mg per kilogram of body wei

8 ay [BID]), voriconazole (10 mg/kg p.o. BID), liposomal amphotericin B (10 mg/kg intraperitoneally [i.

9 cal antigenemia in Uganda were randomized to liposomal amphotericin B (10 mg/kg once) with fluconazol

10 kg/day in three divided doses, combined with liposomal amphotericin B (10 mg/kg, single dose) and flu

11 ungal infections among patients treated with liposomal amphotericin B (11 patients [3.2 percent]) tha

12 ly less frequent among patients treated with liposomal amphotericin B (19 percent) than among those t

13 ransient visual changes than those receiving liposomal amphotericin B (22 percent vs. 1 percent, P<0.

14 greater with amphotericin B (63%) than with liposomal amphotericin B (25%) (P = 0.002).

15 Mortality at 10 weeks trended lower for liposomal amphotericin B (28.2%) versus amphotericin B d

16 phigus foliaceus died despite treatment with liposomal amphotericin B, 3 mg/kg/d, and a young girl wi

17 ter, along with IV caspofungin (50 mg/d) and liposomal amphotericin B (300 mg/d).

18 e mean duration of therapy was 10.8 days for liposomal amphotericin B (343 patients) and 10.3 days fo

19 The patient was treated initially with liposomal amphotericin B, 430 mg daily, but changed to v

20 icantly higher for all patients who received liposomal amphotericin B ($48,962 v $43,183; P =.022).

21 %), caspofungin (24%), voriconazole (8%), or liposomal amphotericin B (5%).

22 with voriconazole than in those treated with liposomal amphotericin B (8 [1.9 percent] vs. 21 [5.0 pe

23 cent with voriconazole and 30.6 percent with liposomal amphotericin B (95 percent confidence interval

24 percent for caspofungin and 33.7 percent for liposomal amphotericin B (95.2 percent confidence interv

25 On day 67 p.t., ITR was discontinued and liposomal amphotericin B (AMB) was initiated.

26 reated with 30 mg/kg body weight intravenous liposomal amphotericin B (AmBisome) divided as 6 equal d

27 nt arms, either a total 40 mg/kg intravenous liposomal amphotericin B (AmBisome; Gilead Pharmaceutica

28 daily amphotericin B deoxycholate and daily liposomal amphotericin B among persons with human immuno

29 ssful treatment were similar (50 percent for liposomal amphotericin B and 49 percent for conventional

30 aggressive surgical and antifungal therapy (liposomal amphotericin B and a broad-spectrum triazole p

31 The outcomes were similar with liposomal amphotericin B and conventional amphotericin B

32 Liposomal amphotericin B and MIL combination for treatin

33 He was treated with liposomal amphotericin B and multiple debridements, with

34 The cost of liposomal amphotericin B and patient risk for developing

35 both in vitro and in vivo antagonism between liposomal amphotericin B and ravuconazole in simultaneou

36 fungal agents (voriconazole, with or without liposomal amphotericin B), and 24 required surgical debr

37 antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be mu

38 riple therapy with intravenous voriconazole, liposomal amphotericin B, and fosmanogepix is recommende

39 s remain limited to pentavalent antimonials, liposomal amphotericin B, and miltefosine.

40 y and safety of caspofungin as compared with liposomal amphotericin B as empirical antifungal therapy

41 nes strongly recommend a single high dose of liposomal amphotericin B as part of preferred treatment,

42 yptococcal meningitis receiving either daily liposomal amphotericin B at 3 mg/kg/day with flucytosine

43 tion was associated with early initiation of liposomal amphotericin B-based therapy combined with sur

44 The patient initially received liposomal amphotericin B, but the infection continued to

45 sed antimicrobials (meropenem, piperacillin, liposomal amphotericin B, caspofungin, and voriconazole)

46 Single-dose liposomal amphotericin B combined with flucytosine and f

47 cryptococcal meningitis with single 10-mg/kg liposomal amphotericin B, combined with oral flucytosine

48 hat a regimen based on a single high dose of liposomal amphotericin B deoxycholate (AmBisome group) w

49 ted with amphotericin B and one treated with liposomal amphotericin B died during induction (P = 0.04

50 pared with 45 of 51 patients (88%) receiving liposomal amphotericin B (difference, 24 percentage poin

51 gnosis, surgery and treatment with high-dose liposomal amphotericin B eradicated the disease.

52 zole, a new second-generation triazole, with liposomal amphotericin B for empirical antifungal therap

53 ceive empirical therapy with conventional or liposomal amphotericin B for the prevention and early tr

54 howed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of

55 ng units (CFU) per milliliter per day in the liposomal amphotericin B group and -0.42 log(10) CFU per

56 nfidence interval [CI], 20.7 to 29.3) in the liposomal amphotericin B group and 117 (28.7%; 95% CI, 2

57 pants had grade 3 or 4 adverse events in the liposomal amphotericin B group than in the control group

58 amined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individual

59 We have evaluated liposomal amphotericin B in 20 patients with DL in an op

60 itutions, one echinocandin in 346 (89%), and liposomal amphotericin B in 301 (78%), with country gros

61 gery in 59% and antifungals in 87% of cases (liposomal amphotericin B in 61%).

62 (WHO) recommended a single 10 mg/kg dose of liposomal amphotericin B in combination with 14 days of

63 Daily liposomal amphotericin B induction demonstrated a simila

64 ty of Mucorales qPCR within seven days after liposomal-amphotericin B initiation was associated with

65 Liposomal amphotericin B is an effective therapy for DL,

66 Liposomal amphotericin B is as effective as conventional

67 city play large roles in determining whether liposomal amphotericin B is cost-effective as first-line

68 First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while

69 s with previous severe infusion reactions to liposomal amphotericin B is unclear.

70 Liposomal amphotericin B (L-AmB) is the drug of choice f

71 activity (EFA) of 3 short-course, high-dose liposomal amphotericin B (L-AmB) regimens for cryptococc

72 ylactic versus therapeutic administration of liposomal amphotericin B (L-AmB) was tested in C57BL/6 m

73 teria, reporting comparisons of fluconazole, liposomal amphotericin B (L-AmB), itraconazole, micafung

74 The optimal dosage of liposomal amphotericin B (LAmB) alone or in combination

75 ty and efficacy of combination therapy using liposomal amphotericin B (LAmB) and MIL for treating PKD

76 ed safety profile and antifungal efficacy of liposomal amphotericin B (LAmB) compared to conventional

77 Since its introduction in the 1990s, liposomal amphotericin B (LAmB) continues to be an impor

78 tolerability of high-dose weekly (10 mg/kg) liposomal amphotericin B (LamB) for antifungal prophylax

79 -derivatized-dendrimer (PDD), complexed with liposomal amphotericin B (LAmB) in an L. major mouse mod

80 been replaced in high-income countries with liposomal amphotericin B (LAmB), which has many advantag

81 cal evidence that the antifungal activity of liposomal amphotericin B (mean EFA, 0.495 [95% confidenc

82 Liposomal amphotericin B monotherapy at 3 mg/kg previous

83 , of whom 201 had available EFA data (n = 46 liposomal amphotericin B; n = 155 amphotericin B deoxych

84 center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant

85 photericin B and 9% of patients treated with liposomal amphotericin B (P = 0.003).

86 When comparing single, high-dose liposomal amphotericin B plus 14 days of flucytosine plu

87 patients who received amphotericin B versus liposomal amphotericin B preparations (100% vs. 89%); ho

88 otericin B and 43 days in those who received liposomal amphotericin B preparations.

89 Liposomal amphotericin B seems to be a less toxic altern

90 hen prospectively screened twice a week, and liposomal amphotericin-B therapy initiated based on a po

91 titers (<=1:80), the addition of single-dose liposomal amphotericin B to fluconazole as pre-emptive t

92 n treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infe

93 We evaluated whether adding single high-dose liposomal amphotericin B to standard pre-emptive flucona

94 P cellular therapy was additive with that of liposomal amphotericin B treatment.

95 The success rate with liposomal amphotericin B was 4-fold higher even when con

96 Although liposomal amphotericin B was considered well tolerated,

97 ouble-blind, comparative, multicenter trial, liposomal amphotericin B was equivalent to conventional

98 Early antifungal treatment with liposomal amphotericin B was pivotal to improve IAPA out

99 Liposomal amphotericin B was started within a median of

100 nts (415 assigned to voriconazole and 422 to liposomal amphotericin B) were evaluated for success of

101 ctive as and generally better tolerated than liposomal amphotericin B when given as empirical antifun

102 d, double-blind, multicenter trial comparing liposomal amphotericin B with conventional amphotericin

103 14.5% (12/83) of participants randomized to liposomal amphotericin B with fluconazole versus 10.6% (

104 The most common regimen in CNS disease was liposomal amphotericin B with flucytosine (93.8%; mean d

105 ta exist on the antifungal activity of daily liposomal amphotericin B with flucytosine induction regi

106 regimen that includes a single high dose of liposomal amphotericin B would be efficacious is not kno